Watch the full podcast episode here.
Iterative Health and GI Alliance have announced a first-of-its-kind strategic alliance to power the largest GI-focused clinical research network in the world—marking a major step forward for how trials are designed, executed, and experienced in gastroenterology.
The announcement was made on The Scope Forward Show by Dr. Jonathan Ng, Founder & CEO of Iterative Health, and Dr. Casey Chapman, Chief Medical Officer of GI Alliance. Together, they outlined a shared vision to embed research directly into clinical care, restoring physician agency while expanding equitable access for patients.
The alliance brings together 80 research sites across the globe, unified by a shared platform for trial execution at the point of care. Rather than operating as a traditional financial partnership, the collaboration represents a systemic intervention—one designed to remove operational friction, address persistent recruitment bottlenecks, and elevate research as a core component of everyday GI practice.
“It’s not about trial volume. It’s about raising the standard of care through research.”
— Dr. Jonathan Ng, Founder & CEO, Iterative Health
“If this was just about ROI, we wouldn’t be here. This is about building the future—with physicians, for patients.”
— Dr. Casey Chapman, CMO, GI Alliance
Two years in the making, the partnership reflects deep alignment between the organizations around physician empowerment, patient-first design, and real-world impact. By integrating trials into community-based care—particularly in areas such as IBD and liver disease—the alliance positions gastroenterology as a launchpad for the next generation of drug innovation.
Key themes discussed in the episode include:
- Why research must happen where care is delivered
- The importance of empowering physicians as research leaders
- Lessons learned about why technology alone cannot fix broken systems
- How listening-first partnerships outperform profit-first models
This announcement signals more than a milestone for Iterative Health and GI Alliance—it represents a broader shift for GI research at large.
Together, Iterative Health and GI Alliance are building a future where research and care move forward—side by side.
About Iterative Health
Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. Today, Iterative Health is based in Cambridge, Massachusetts, and New York City with 250+ employees world-wide.
To learn more or explore a partnership, please visit our Contact page.